Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

27
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
27
Subviral Agents01:29

Subviral Agents

723
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
723
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

4
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
4

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is less always more? Ceftazidime/avibactam alone or in combination to treat infections caused by Pseudomonas aeruginosa: a retrospective observational multi-centre cohort study.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Andes virus-associated cardiopulmonary syndrome: diagnostic approaches, clinical management, and evidence gaps-a scoping review.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

When Hours Matter: A 24/7 Laboratory and Fast-Track Diagnostic Pathway for Blood Cultures in Critical Patients.

Antibiotics (Basel, Switzerland)·2026
Same author

Necrotizing Fasciitis in Northern Italy: Clinical Characteristics, Risk Factors, and Prognostic Value of the LRINEC Score-A Single-Center Retrospective Case Series.

Infectious disease reports·2026
Same author

Seven versus fourteen days for resistant bloodstream infections: what do we actually know? A scoping review.

Infection·2026
Same author

Case Report: Beyond conventional diagnostics: mNGS support in a complex immunocompromised patient diagnosis.

Frontiers in medicine·2026

Related Experiment Video

Updated: Mar 22, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Emerging biological agents for hepatitis C.

Valentina Zuccaro1, Paola Columpsi1, Alice Apollinari1,2

  • 1a Dipartimento Malattie infettive , Fondazione IRCCS Policlinico San Matteo Pavia , Pavia , Italia.

Expert Opinion on Emerging Drugs
|April 30, 2016
PubMed
Summary

New antiviral treatments for chronic Hepatitis C virus (HCV) infection offer high sustained virological response (SVR) rates. Further research is needed to optimize individual patient care and understand long-term outcomes.

Keywords:
DAA’sHCVdirect antiviral agentstherapy

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Related Experiment Videos

Last Updated: Mar 22, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Direct-acting antiviral agents have revolutionized chronic Hepatitis C virus (HCV) infection treatment.
  • Current therapies demonstrate high efficacy and tolerability, achieving significant sustained virological response (SVR) rates.
  • Despite advancements, unmet medical needs persist, driving ongoing research for novel agents and combinations.

Purpose of the Study:

  • To review emerging antiviral compounds for HCV infection currently in development.
  • To identify new therapeutic strategies and combinations for managing chronic HCV.
  • To assess the current landscape of investigational HCV treatments.

Main Methods:

  • Conducted a literature search for novel antiviral compounds targeting HCV infection.
  • Utilized PubMed and the clinicalTrials.gov registry to identify medications in development.
  • Focused on studies including Phase I/II trials and select randomized Phase III trials.

Main Results:

  • Identified numerous antiviral compounds and combinations undergoing clinical investigation for HCV.
  • Highlighted the ongoing development of new therapeutic options beyond currently approved regimens.
  • Indicated a continuous effort to expand the armamentarium against HCV infection.

Conclusions:

  • Further research is essential to elucidate the impact of HCV eradication on disease progression.
  • Increased confidence regarding drug-drug interactions with new antiviral agents is required.
  • Individualized treatment strategies are crucial to optimize patient outcomes, focusing on viral suppression, halting liver disease progression, and improving overall health status.